Innovación en el tratamiento de los Sarcomas de Partes Blandas - page 19

2ª Línea
1.0
0.8
0.6
0.4
0.2
Survival Probability
0
3
6
9
12 15
21 24 27 30 33 36 39 42 45
18
Eribulin
Dacarbazine
Progression-Free Survival, months
Eribulin
Dacarbazine
Median OS (months)
13.5
11.5
HR (95% CI)
0.768 (0.618, 0.954)
Stratified
p
-value
0.0169
PFS events
329
Median PFS Trabectedin
4.2 months
Median PFS Dacarbazine
1.5 months
1...,9,10,11,12,13,14,15,16,17,18 20,21,22,23,24,25,26,27,28,29,...36
Powered by FlippingBook